Neuropace Inc Stock Price, News & Analysis

NeuroPace (Nasdaq: NPCE) announced on October 19, 2021, the appointment of Lisa Andrade to its Board of Directors, effective November 1, 2021. Andrade brings over 25 years of experience in the medtech sector and is currently the CEO of M33. She has held key positions at St. Jude Medical and possesses expertise in strategy, product development, and marketing. Additionally, Evan Norton is resigning from the board. Andrade expressed excitement about contributing to NeuroPace’s mission to transform epilepsy care with its RNS® System, approved for drug-resistant focal epilepsy.

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced participation in three significant healthcare conferences. The schedule includes:

• Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 9:20 a.m. ET.
• Morgan Stanley Global Healthcare Conference on September 14, 2021, at 3:30 p.m. ET.
• Baird Global Healthcare Conference on September 15, 2021, at 2:35 p.m. ET.

Live audio will be available on the company’s website, with archives accessible for at least 90 days post-event.

NeuroPace, based in Mountain View, reported a 65% revenue increase to $12.6 million for Q2 2021. Initial implant revenues surged 100% to $9.2 million. The company received a $9.3 million grant from NIH's BRAIN Initiative to evaluate its RNS System for Lennox-Gastaut Syndrome. Despite increased revenues, operating expenses rose to $14 million, leading to a net loss of $8.5 million. NeuroPace forecasts a full-year revenue of approximately $47 million, a 14% growth year-over-year, but anticipates declining replacement implant revenues due to extended device battery life.

NeuroPace, Inc. (Nasdaq: NPCE) will report its financial results for Q2 2021 on August 12, 2021, after market close. A conference call with management will follow at 1:30 p.m. PT/4:30 p.m. ET, accessible by dialing (844) 955-2173 for domestic or (914) 987-7949 for international participants. NeuroPace specializes in innovative medical devices for epilepsy, with its RNS System being the only brain-responsive neuromodulation platform available, providing personalized treatment to patients with drug-resistant epilepsy.

NeuroPace has received a $9.3 million NIH grant through the BRAIN Initiative to evaluate its RNS® System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy. This Investigational Device Exemption (IDE) study is set to enroll patients in the second half of 2022. The study will be the first to assess neuromodulation in LGS patients and aims to provide insights into personalized treatment. The FDA must approve the study, with the possibility of a larger clinical trial following positive results.

NeuroPace, Inc. (NPCE) reported Q1 2021 financial results, showing total revenue of $11.2 million, a 12% increase from Q1 2020. Initial implant revenue reached $8.1 million, marking a 23% rise. The company successfully completed its IPO, raising approximately $105 million. Despite positive growth, net loss widened to $8.8 million, up from $6.7 million year-over-year. For 2021, total revenue guidance is set at $47 million, reflecting 14% growth. Replacement implant revenue is expected to decline by 16%.

NeuroPace, Inc. (Nasdaq: NPCE) will report its Q1 2021 financial results on June 3, 2021, before market open. A conference call will be held at 5:00 a.m. PT (8:00 a.m. ET) to discuss the results, with investors able to join by dialing (844) 955-2173 for domestic calls or (914) 987-7949 for international calls, using ID: 1485513. NeuroPace specializes in a brain-responsive neuromodulation platform aimed at treating epilepsy, offering a personalized approach to managing debilitating seizures.

NeuroPace, Inc. (Nasdaq: NPCE) successfully completed its initial public offering (IPO) on April 26, 2021, by closing the sale of 6,900,000 shares at $17.00 each. This offering included the full exercise of underwriters' options for 900,000 additional shares, resulting in gross proceeds of approximately $117.3 million. The company focuses on innovative products for epilepsy treatment, with its RNS System being the first brain-responsive platform available. The stock began trading on April 22, 2021.

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, announced its initial public offering (IPO) of 6,000,000 shares at $17.00 each, totaling $102 million in gross proceeds. The IPO is expected to close on April 26, 2021. NeuroPace has also granted underwriters an option to purchase an additional 900,000 shares. Trading on Nasdaq is set to begin on April 22, 2021. J.P. Morgan and Morgan Stanley lead the offering, with registration statements already filed with the SEC.